IPO Filing Floodgates: Bronchus Technologies, Inc. (LUNG)

Bronchus Technologies, Inc. filed yesterday for an initial public offering of up to $86.25 million for filing purposes.  It has the proposed ticker of "LUNG" on NASDAQ, and the lead underwriters are Lehman Brothers and Bear Stearns, and co-managers are Jefferies and RBC Capital Markets. 

Broncus Technologies is a medical technology company focused on developing and commercializing minimally-invasive medical devices for emphysema and other lung diseases.

"We believe our patented treatment method, Airway Bypass, will be the first minimally-invasive procedure for the treatment of homogeneous, or diffuse, emphysema, the form of the disease experienced by the majority of emphysema patients. We also believe that patients with heterogeneous, or localized, emphysema may also benefit from Airway Bypass. Additionally, we believe that several of our products being developed for Airway Bypass may be used in or adapted for the diagnosis and management of other lung diseases, including pulmonary hypertension and lung cancer."

If you wish to join our open email distribution list we often provide more detailed IPO and spin-off coverage.  These are frequently lead-ins to our subscriber-based "Special Situation Investing Newsletter" where we cover buyouts, spin-offs, back-door plays into IPO’s, reorganizations, and more.

Jon C. Ogg
November 21, 2007